

**A V E X A**

Avexa Limited  
ABN 53 108 150 750  
576 Swan Street Richmond  
Victoria Australia 3121

Telephone 61 3 9208 4300  
Facsimile 61 3 9208 4004  
Website [www.avexa.com.au](http://www.avexa.com.au)

## ASX Release

### Stephen Kerr appointed Company Secretary

**Melbourne, Australia, 20 March, 2009**, Australian biotech company Avexa Limited (ASX: AVX) announced today that in keeping with the announcement on 10 March, 2009, Mr Stephen Kerr has replaced Mr. Alan Boyd, as Chief Financial Officer (**CFO**) and Company Secretary. As part of the transition Mr Boyd today also formally resigned as a Director.

Mr Boyd will remain at Avexa until the third of April to complete a three week handover period and ensure a smooth and seamless transition of the CFO and Company Secretarial roles.

#### For more information:

Dr. Julian Chick  
Chief Executive Officer  
+61 3 9208 4300

[www.avexa.com.au](http://www.avexa.com.au)

**Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including its HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC), an anti-HIV drug which has successfully completed the 48 week dosing of its Phase 2b trial and is currently in Phase 3 trials. The company recently released impressive 96 week data from its Phase IIb trial and is expecting initial Phase III trial results in the 2<sup>nd</sup> quarter, 2009.**